With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Attorney General Keith Ellison reached a settlement with insulin manufacturers Eli Lilly, Sanofi, and Novo Nordisk, which ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Huge crowds have come out to Chinatown for Lunar New Year as new political faces take office. She made the look her own with ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...